Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
The last paragraph of this morning's RNS is very interesting! Sounds very confident to me that they are past design freeze and preparing for clinical validation.
"I am also very pleased that the CONDOR programme will support the clinical validation of the rapid saliva-based COVID-19 antigen test strip that we are developing with Cytiva. This, combined with other collaborations that we are putting in place, will provide us with access to a sufficient number of COVID-19 patient samples to allow us to quickly clinically validate the saliva rapid test."
Added to filter list, and also another paid cross-ramper richmanpoorman
You can all ignore this idiot MMgames. Momentum day trading pump n dump kinda fella. Check out his posts on SAE when that popped on news.. "easy 30p" blablaetcetc to try suck in newcomers. He then went to TOM, EUA.. rainbow chasing.
This is still the only COVID play thats actually making sales. No hype, just pure cash! I expect buying into the bell as traders lock in SNG profits and put back in here.
Can't believe my eyes here. Well done to all those that suffered all these months, me included after paying 70p back at the April 14th peak. I stubbornly held on and was red right from the off.. until today.
Just top sliced at 210p and rest is a free trade. Can't wait to see where this ends up. Enjoy the ride all!
@CocaColaKid thats why I'm invested here. It's the only 'safe' covid play for me - sales, profit, and new products too. I've been happy to hold here and most were expecting a great June number - 10m+ capacity so even the most bearish would have expected £40m+ sales. So £22.5m is a big negative surprise. Sure the 1H +900% in sales looks great, but even through to May it was already +400% vs 1H19 (£40m vs £6.3m), but it really should have been +1,100% increase if they had achieved £40m in sales for June.
Like I said, something strange happened in June which is unclear, and if it continues, that will have significant impact on valuations (pretty much halving expectations). I'm hoping its a one off but with no news expected on this front until either the full interims or next monthly update - it will be a worry to see how the stock moves in the coming fortnight. Only positive I can see is they announce saliva-based testing and getting a chunk of that £5bn UK govt tender.
@Simple00, £3.80/shr is meaningless. Thats just 1x sales you are basing on. Remember the saying.. sales is vanity, profit is sanity, cash is reality. Only good thing here is that NCYT is generating a lot of cash, and the last RNS said there is "expected to be greater cash generation in the second half of the year". How much remains to be seen, but I would estimate a cash balance of around £60-70m by year end at a minimum.
Seriously - you all say the RNS was good/great.. Really? June sales £22.5m really is pants. Until there's a very good reason for this - I expect investors to stay on the sidelines here.
Quite telling the silence from the previous positive posters ShaunP, ggggg21 etc. Have the sold and moved on?
Technically yes a blue day but barely. As has happened with recent RNS's, any strength was sold into, and looking at the volume chart on Euronext, it seems every drop was on volume in France today so I sense risks are to the downside near term. Next scheduled RNS is the full interims so thats due towards end of the month. If we are rangebound til then, I'll be happy.
@S4KSecurity what were your estimates for June? I think everyone that follows this company and done the research would have expected £40m+ in revenues. You say "upward trend for the sales still continues", but if anything June is downward!
With testing globally ramping up - not sure how NCYT only reported £22.5m. Strange no mention of orders this time either. Usually it's been orders for, and contracted to deliver. This was £80m last month.
Anyone else want to share thoughts on this? I see suspicious bumping/creating of other ramping posts that seems to focus 900% sales growth while June trend is the concern here.
I'm not surprised by the market reaction here. June sales is underwhelming and I'm not sure why its so low. Either they failed to sell all 10m capacity (strange as Roche says they cant make tests quick enough) or pricing is a disaster at <£3! So even worse than May at my estimated £5.5 level.
Anyways, was wondering what ShaunP though of it as I always considered his spreadsheet quite conservative, and these June numbers came below that.
Started adding names to my list today, and no doubt the idiots/TW crew will be out in force over the weekend. Save e some time and share your list with me.
Mine so far:
PL75
alwayswinning
Global_2017
mortgagefreeman
Ajok
I've not been very active on this board since last week and I just want to say I've never been more relaxed holding this share. Sona's test has confirmed that a saliva (even though swab based) lateral flow test is viable, and indeed the sensitivity and specificity at 96% is astounding. I think most of us here did not expect Sona to achieve that.
I really can't see downside now to Avacta. Our Affimers have many benefits over the MAbs that Sona's test use, so in the worst case scenario Sona can switch to Affimers if their test is ever to be mass produced to a quantity to meet global demand. I highly doubt Sona have the manufacturing capability anyhow, but for me the risk here was always whether a LFT was viable. Sona has answered that and we are all just awaiting that RNS any day now.
So switch off, filter the nonsense posters here, and check in when that key RNS drops.
Precisely RichKen. I just can't fathom how Avacta cannot make the best in class LFT. The way the company has communicated via news/videos, and the RNSs.. it would be a massive negative impact on management/company/Affimer technology credibility if the test fails to materialise/work.
As you rightly say, there's plenty of imminent newsflow to satiate investors appetite here. If Avacta cannot come up with the best test, I'm not sure how anybody else can. And that would be terrible for getting us out of this covid mess.
In any antigen LFT, there needs to be a reagent that binds to the spike protein. Your alternatives are antibodies, or Affimers. I have a feeling that Avacta's antigens will be in demand precisely for this reason, and why the company is ramping up manufacturing for this eventuality.
So Mologic, Abingdon/Imperial or whoever wants to create a POC LFT, will need to make that decision.